MGVS's two leading products, MultiGeneAngio and MultiGeneGraft have been approved by the FDA for clinical studies as treatment for peripheral arterial disease. Both products target large and growing patient populations with unmet needs.

  MultiGeneAngio: a cell therapy product for alleviating symptoms and signs of ischemia in patients with peripheral arterial disease (PAD) and coronary artery disease (CAD).

  MultiGeneGraft: a biosynthetic vascular graft lined with the patient’s own endothelial cells, providing improved biocompatibility for patients undergoing bypass surgery for PAD, as well as for renal disease patients who need hemodialysis access site.